ResMed Management Performance Evaluation

RMD -- USA Stock  

USD 100.93  4.10  3.90%

Analysis of ResMed manpower and management performance can provide insight into ResMed stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with ResMed future performance. Additionally take a look at Your Equity Center.

ResMed Management Effectiveness

The company has Return on Asset of 10.72 % which means that on every $100 spent on asset it made $10.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.7 % implying that it generated $15.7 on every 100 dollars invested.

ResMed Workforce Comparison

ResMed is rated below average in number of employees category among related companies. The total workforce of Medical Instruments & Supplies industry is at this time estimated at about 143,583. ResMed holds roughly 5,940 in number of employees claiming about 4% of all equities under Medical Instruments & Supplies industry.

ResMed Profit Margins

The company has Net Profit Margin of 13.49 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 29.07 % which entails that for every 100 dollars of revenue it generated 0.29 of operating income.

ResMed Insider Trading

ResMed Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of seventeen. ResMed Price Series Summation is a cross summation of ResMed price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

ResMed Stakeholders

Michael Farrell CEO and Director
Peter Farrell Non-Executive Chairman of the Board
Rob Douglas President COO
Jim Hollingshead President - Americas
Don Darkin President - Sleep-disordered Breathing Strategic Business Unit
Anne Reiser President Europe
Raj Sodhi President ? Software as a Service (SaaS) Business and CTO
Richard McHale President ? Respiratory Care
Donald Darkin President ? innovation & operations
Brett Sandercock CFO and Principal Accounting Officer
Robert Douglas Pres and COO
John Wareham Independent Director
Ronald Taylor Lead Independent Director
Christopher Roberts Independent Director
Gary Pace Independent Director
Chris Roberts Independent Director
Agnes Lee Senior Director - Investor Relations
Carol Burt Independent Director
Rich Sulpizio Independent Director
Ron Taylor Lead Independent Director
Jack Wareham Independent Director
Karen Drexler Director
Richard Sulpizio Independent Director
David Pendarvis Chief Admin. Officer, Global General Counsel and Secretary

ResMed Leadership

ResMed Top Executives

  Michael Farrell  CEO
CEO and Director
  Peter Farrell  Chairman
Non-Executive Chairman of the Board

ResMed Tenure Analysis

ResMed Employment Tenure

ResMed employes about 5940 people. The company is managed by 24 executives with total tenure of roughly 157 years, averanging almost 6.0 years of service per executive having 247.0 employee per reported executive.

ResMedManpower Efficiency

Return on ResMed Manpower

Revenue Per Employee410.9 K
Revenue Per Executive97.5 M
Net Income Per Employee78.8 K
Net Income Per Executive13.1 M
Working Capital Per Employee131.6 K
Working Capital Per Executive32.6 M

Per Employee

ResMed Per Employee Growth Over Time

Net Income Per Employee

Revenue Per Employee

Additionally take a look at Your Equity Center. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com